Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 8;18(12):1632-41.
doi: 10.1016/j.str.2010.09.017.

Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody

Michael M Freeman  1 , Michael S Seaman, Sophia Rits-Volloch, Xinguo Hong, Chia-Ying Kao, David D Ho, Bing Chen
Affiliations

Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody

Michael M Freeman et al. Structure. .

Abstract

Ibalizumab is a humanized, anti-CD4 monoclonal antibody. It potently blocks HIV-1 infection and targets an epitope in the second domain of CD4 without interfering with immune functions mediated by interaction of CD4 with major histocompatibility complex (MHC) class II molecules. We report here the crystal structure of ibalizumab Fab fragment in complex with the first two domains (D1-D2) of CD4 at 2.2 Å resolution. Ibalizumab grips CD4 primarily by the BC-loop (residues 121-125) of D2, sitting on the opposite side of gp120 and MHC-II binding sites. No major conformational change in CD4 accompanies binding to ibalizumab. Both monovalent and bivalent forms of ibalizumab effectively block viral infection, suggesting that it does not need to crosslink CD4 to exert antiviral activity. While gp120-induced structural rearrangements in CD4 are probably minimal, CD4 structural rigidity is dispensable for ibalizumab inhibition. These results could guide CD4-based immunogen design and lead to a better understanding of HIV-1 entry.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Inhibition of representative HIV-1 isolates by ibalizumab IgG and Fab
HIV-1 primary isolates, Du156.12 (clade C), QH0692.42 (clade B), ZM53M.PB12 (clade C) and Q769.d22 (clade A) were analyzed for inhibition by the anti-CD4 monoclonal antibody ibalizumab using a luciferase-based virus neutralization assay with TZM.bl cells. Serial dilutions of ibalizumab in the bivalent IgG form (filled square) or the monovalent Fab form (open square) were tested for neutralization against each virus. 50% of inhibition is indicated by a dashed, horizontal line. IC50 values and MPI (maximum percent inhibition) are summarized in Table 1. The experiments were repeated twice with similar results. See also Figure S1 and Table S2.
Figure 2
Figure 2. Structure of the complex of 2 domain CD4 and the Fab fragment of ibalizumab
(A) Top and side views of the overall structure of 2D CD4 in complex with ibalizumab Fab, shown in ribbon representation. CD4 is in green (lighter green for D2 and darker green for D1), the heavy chain of ibalizumab in red, and the light chain in magenta. The BC-loop in the second domain of CD4, which constitutes the core epitope, and the CDR loops of ibalizumab are all indicated. (B) Surface representation of the complex. CD4 and ibalizumab are shown in the same color scheme as in (A). See also Figure S2 and Figure S4, and Table S1.
Figure 3
Figure 3. Close-up of major contacts between CD4 and ibalizumab
(A) Residues making direct contacts between the heavy- and light- chains of ibalizumab and the BC-loop (residues 121-125) of D2 in CD4. The heavy and light chains of ibalizumab are shown by surface representation in red and magenta, respectively, and the residues that make contacts with CD4 are also shown by stick model in the same color scheme. The BC-loop of CD4 is in green in ribbon diagram and the residues interacting with ibalizumab are shown by stick model with carbon atoms in yellow, nitrogen in blue and oxygen in red. (B) Contacting residues between the FG loop (residues 164, 165) of D2 in CD4 and the ibalizumab heavy-chain. The residues that make direct contacts with the FG loop of CD4 in the heavy chain are shown by stick model in red. The FG loop of CD4 is shown in ribbon diagram in green with residues 164 and 165 in stick model in the same color scheme as in (A). The conformation of the two residues in the unbound CD4 is also shown in cyan; a flip of the loop upon binding to ibalizumab is evident. See also Figure S3 and Table S1.
Figure 4
Figure 4. Impact of flexibility in the CD4 ectodomain on HIV-1 inhibition by ibalizumab
To introduce flexibility in the ectodomain of CD4, four variants with its D3-D4 (residues 179-365) substituted by a flexible linker, GGGGS (CD4-L1), GGGGSGGGGSGGGGS (CD4-L2), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (CD4-L3) and GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (CD4-L4) were generated. Two additional CD4 variants were also constructed with either a 5-residue (residues 367-371; TPVQP) deletion (CD4-Δ5) or the entire D3-D4 and TM (residues 179-433) replaced by a human CD8α hinge region and TM (residues 115-214) (CD4-CD8TM). ACTOne CCR5 cells were transfected with wildtype CD4 and six variants. Surface expression levels of CD4 and CCR5 were detected by fluorescence-activated cell sorting (FACS) analyses and the mean fluorescence intensity (MFI) values are summarized. The relative infectivity of these target cells by a recombinant HIV-1 Env pseudovirus, SC422661.8, expressing the firefly luciferase reporter gene is shown by relative luminescence units (RLU). Inhibition of this HIV-1 Env pseudovirus by ibalizumab IgG are reported as IC50 values and MPI (maximum percent inhibition). The experiments were repeated twice with similar results and one set of data is shown. See also Figures S8 and S9.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aoki ST, Settembre EC, Trask SD, Greenberg HB, Harrison SC, Dormitzer PR. Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab. Science. 2009;324:1444–1447. - PMC - PubMed
    1. Ashish, Juncadella IJ, Garg R, Boone CD, Anguita J, Krueger JK. Conformational rearrangement within the soluble domains of the CD4 receptor is ligand-specific. J Biol Chem. 2008;283:2761–2772. - PubMed
    1. Boon L, Holland B, Gordon W, Liu P, Shiau F, Shanahan W, Reimann KA, Fung M. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology. 2002;172:191–203. - PubMed
    1. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, Williams C, Chisholm P. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol. 1992;149:1779–1787. - PubMed
    1. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997;89:263–273. - PubMed

Publication types

MeSH terms